Literature DB >> 16236281

Response of human rhabdomyosarcoma cell lines to retinoic acid: relationship with induction of differentiation and retinoic acid sensitivity.

Stéphanie Ricaud1, Barbara Vernus, Anne Bonnieu.   

Abstract

The ability of retinoids to induce growth inhibition associated with differentiation of diverse cell types makes them potent anti-cancer agents. We examined the effect of retinoic acid (RA) in cell lines derived from rhabdomyosarcoma (RMS), a malignant soft-tissue tumor committed to the myogenic lineage, but arrested prior to terminal differentiation. We showed that several RMS derived cell lines, including RD human rhabdomyosarcoma cells, are resistant to the growth-inhibitory and differentiation effects of RA. We established that this RA-resistance correlates with reduced expression and activity of RA-receptors in RD cells. We stably expressed either RARalpha, RARbeta, RARgamma, or RXRalpha expression vector into RD cells and found that only RARbeta or RARgamma induced a significant RA growth arrest without promoting differentiation indicating that changes in the amounts of RARs and RXRs are not sufficient to determine the RA myogenic response of rhabdomyosarcoma cells. Activation of RD cell differentiation by ectopic MRF4 expression enhanced RA-receptor activity and led to RA induction of differentiation. These studies demonstrate that RA-resistance of RD cells is linked to their lack of differentiation and suggest that the differentiation-promoting activity of RA requires factors other than RAR-RXR heterodimers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236281     DOI: 10.1016/j.yexcr.2005.09.011

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  6 in total

1.  Activation of RXR and RAR signaling promotes myogenic differentiation of myoblastic C2C12 cells.

Authors:  Gao-Hui Zhu; Jiayi Huang; Yang Bi; Yuxi Su; Yi Tang; Bai-Cheng He; Yun He; Jinyong Luo; Yi Wang; Liang Chen; Guo-Wei Zuo; Wei Jiang; Qing Luo; Jikun Shen; Bo Liu; Wen-Li Zhang; Qiong Shi; Bing-Qiang Zhang; Quan Kang; Jing Zhu; Jie Tian; Hue H Luu; Rex C Haydon; Yuan Chen; Tong-Chuan He
Journal:  Differentiation       Date:  2009-06-27       Impact factor: 3.880

2.  Therapeutic Implications of PPARgamma in Human Osteosarcoma.

Authors:  Eric R Wagner; Bai-Cheng He; Liang Chen; Guo-Wei Zuo; Wenli Zhang; Qiong Shi; Qing Luo; Xiaoji Luo; Bo Liu; Jinyong Luo; Farbod Rastegar; Connie J He; Yawen Hu; Barrett Boody; Hue H Luu; Tong-Chuan He; Zhong-Liang Deng; Rex C Haydon
Journal:  PPAR Res       Date:  2010-02-16       Impact factor: 4.964

Review 3.  Neuronal differentiation of synovial sarcoma and its therapeutic application.

Authors:  Tatsuya Ishibe; Tomitaka Nakayama; Tomoki Aoyama; Takashi Nakamura; Junya Toguchida
Journal:  Clin Orthop Relat Res       Date:  2008-06-19       Impact factor: 4.176

4.  A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro.

Authors:  Adele P Williams; Alicia M Waters; Jerry E Stewart; Venkatram R Atigadda; Elizabeth Mroczek-Musulman; Donald D Muccio; Clinton J Grubbs; Elizabeth A Beierle
Journal:  J Surg Res       Date:  2018-03-26       Impact factor: 2.192

5.  Cell-based small-molecule compound screen identifies fenretinide as potential therapeutic for translocation-positive rhabdomyosarcoma.

Authors:  David Herrero Martín; Aleksandar Boro; Beat W Schäfer
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

6.  MicroRNA-27a Contributes to Rhabdomyosarcoma Cell Proliferation by Suppressing RARA and RXRA.

Authors:  Lucia Tombolan; Matteo Zampini; Silvia Casara; Elena Boldrin; Angelica Zin; Gianni Bisogno; Angelo Rosolen; Cristiano De Pittà; Gerolamo Lanfranchi
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.